Biogen Appoints Anabella Villalobos Senior Vice President, Biotherapeutic & Medicinal Sciences
Biogen (NASDAQ:BIIB) today announced the appointment of Anabella Villalobos, Ph.D., as senior vice president, Biotherapeutic & Medicinal Sciences (BTMS). Dr. Villalobos will lead Biogen’s BTMS organization in the delivery of high-quality, differentiated molecules to the clinic. She will report to Michael Ehlers, M.D., Ph.D., executive vice president, Head of Research and Development.
“We are excited to have Anabella Villalobos join us at Biogen,” said Dr. Ehlers. “Anabella is a world-class drug hunter, a proven leader in medicinal sciences, and a champion of scientific innovation. Her experience in neuroscience and passion for drug discovery will help us create and advance the next generation of breakthrough medicines.”
Dr. Villalobos joins Biogen from Pfizer Worldwide Research and Development where she most recently served as Vice President and Head of Medicinal Synthesis Technologies. With over 25 years of industry experience in the areas of neuroscience and medicinal chemistry, she has been instrumental in the development of clinical candidates for Alzheimer’s disease, Parkinson’s disease, schizophrenia, and pain.
“Biogen has been an absolute pacesetter in developing breakthrough neurology medicines in the forms of biologics, small molecules, and new anti-sense oligonucleotide therapies for patients.” said Dr. Villalobos. “I am honored to lead Biotherapeutic & Medicinal Sciences, and I look forward to accelerating our neuroscience discovery to find new approaches for the most challenging conditions of the brain.”
Before joining industry, Dr. Villalobos received a BS in Chemistry from the University of Panama, a Ph.D. in Medicinal Chemistry from The University of Kansas, and synthetic organic chemistry training at Yale University as a National Institutes of Health Postdoctoral Fellow.
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology, and today the company has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. For more information, please visit www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook, YouTube.
Biogen Safe Harbor
This press release contains forward-looking statements, made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements relating to Biogen’s business activities and potential of our commercial business and pipeline programs. These forward-looking statements may be accompanied by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “except,” “forecast,” “intend,” “may,” “plan,” “potential,” “possible,” “will” and other words and terms of similar meaning. You should not place undue reliance on these statements. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product.
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation: risks relating to management and key personnel changes; failure to compete effectively; difficulties in obtaining and maintaining adequate coverage, pricing and reimbursement for our products; potential future healthcare reforms; the occurrence of adverse safety events; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; uncertainty of success in developing, licensing or acquiring other product candidates or additional indications for existing products; delay in approval of our drug candidates; product liability claims; and third party collaboration risks. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in Biogen’s most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. These statements are based on our current beliefs and expectations and speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Enamine and TBD Biodiscovery Collaborate to Provide GMP-Based Services20.6.2018 11:17 | Pressemelding
Enamine Ltd., a chemical research organization and producer of novel building blocks and screening libraries, and TBD Biodiscovery, a premium GMP manufacturer of fine chemicals including chemical active pharmaceutical ingredients (APIs), today announced they have entered into a collaboration agreement. The partnership aims to manage the transition of chemical synthesis of novel intermediates from laboratory to bulk scale under GMP standards utilizing Enamine’s know-how and process development expertise. This will help researchers meet the manufacturing feasibility criteria required for drug candidate selection, providing a rapid and cost effective scaled supply of new compounds. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180619005582/en/ Enamine’s catalogue of building blocks is the largest in the world and has been widely used by pharmaceutical companies for more than 15 years to develop lead compounds and drug candidat
ABB and Kawasaki Create World’s First Common Interface for Collaborative Robots20.6.2018 11:00 | Pressemelding
ABB and Kawasaki Heavy Industries, both global leading players in industrial automation and robotics, are showcasing the world’s first common collaborative robot operating interface at automatica in Munich, Germany from June 19-22, 2018. The common interface will also help address the shortage of skilled workers in many industries. In Japan for example, one person in five is within a decade of retirement. Demand for collaborative robots has outpaced the rapidly-growing industrial robot market, as easier-to-use robots open doors to new users. The fact that collaborative robots can be programmed and operated by people without specialized training helps small and medium enterprises, in particular, to leapfrog traditionally longer industrial robot learning curves. Collaborative robots (cobots) that can be operated by nearly any user can help offset labor shortages. Their flexibility to work nearly anywhere in a factory without safety barriers also makes them ideal for meeting sudden and un
CORRECTING and REPLACING Deutsche Bank Moves Reconciliation Services to SmartStream to Further Improve Processing and Reduce Costs20.6.2018 10:38 | Pressemelding
First paragraph, first sentence of release should read: As part of its transformation strategy, Deutsche Bank has selected SmartStream ... (instead of 'As part of a wider strategy to adopt industry utilities, Deutsche Bank has selected SmartStream ...'). The corrected release reads: DEUTSCHE BANK MOVES RECONCILIATION SERVICES TO SMARTSTREAM TO FURTHER IMPROVE PROCESSING AND REDUCE COSTS As part of its transformation strategy, Deutsche Bank has selected SmartStream Technologies’ Centre of Excellence (CoE) to provide an off-site operations platform - including three services which will allow the bank to streamline, simplify and reduce the costs of its reconciliations environment. With the growth in volume of reconciliations, the processing of large quantities of data has become complex. Many financial institutions are exploring utilities to ensure accuracy and cost savings. With the addition of the CoE to Deutsche Bank, SmartStream will provide the bank with three distinct managed servic
Hotelsclick.com: You Can Pay the Hotel with Amazon Pay20.6.2018 10:32 | Pressemelding
Hotelsclick.com, the Italy-based online booking for hotels, has integrated Amazon Pay into its payment methods, becoming one of the first OTA in Europe offering this service. Besides traditional payment methods, such as credit cards (included Amex) and Paypal, users that book a hotel on Hotelsclick.com and hold an Amazon account can choose Amazon Pay to complete the reservation: they only need to enter their Amazon username and password during the checkout process on Hotelsclick.com and the transaction will be carried out quick and safe. As a matter of fact, making an online reservation will be more and more easy thanks to Amazon Pay. Users will no longer need to enter multiple password or other payment details: all information will be automatically taken from their Amazon account. “We are very proud to bring Amazon Pay to our users who visit us on their PCs and mobile. Customers’ experience is our main concern: adding Amazon Pay we are confident we can consistently improve it, making
UEC Presents Its Latest Solution for Gas Transportation and Power Generation at MIOGE 201820.6.2018 09:55 | Pressemelding
United Engine Corporation of Rostec Corporation takes part in the 15th Moscow International Oil and Gas Exhibition (MIOGE 2018). There it will demonstrate gas turbine gas compressor and power generating sets, which are the most promising on the Russian and foreign markets. UEC's exhibition booth presents layouts of gas pumping unit GPA-16, Katangli power facility, and Novoprivodinskaya compressor station. The companies of Russian fuel and energy complex —Gazprom, NC Rosneft, Lukoil, Surgutneftegas and others — are the main consumers of power and gas pumping units produced by UEC. To date, Gazpom uses around 1,500 industrial engines manufactured by the corporation. UEC is going to increase the share of gas turbine industrial equipment in the total volume of its supplies. The corporation is actively performing its activities aimed at entering foreign markets. In May 2018, UEC introduced its latest developments at the exhibitions Iran Oil Show in Tehran, Oil & Gas Uzbekistan in Tashkent a
AI Expo: What Not to Miss at the AI Expo Europe Next Week Including Female Expert Speakers20.6.2018 09:00 | Pressemelding
Arriving in Amsterdam next week on the 27-28 June, the second annual AI Expo Europe event will be co-hosted with two co-located events covering the IoT and Blockchain ecosystem; IoT Tech Expo & Blockchain Expo. With over 9,000 top-level attendees already registered including CTO’s, CDO’s, Heads of Innovation & Technology, IT Directors, Developers, Start-Up’s, VC’s, OEM’s across a range of industries including but not limited to; Marketing, Automotive, HR & Recruitment, Finance, Insurance, Government, Public Sector, Retail, Industrial, Healthcare, Education, Cyber Security and Developer platforms. The AI Expo will showcase the most cutting-edge technologies from more than 300 exhibitors and provide insight from over 300 speakers sharing their unparalleled industry knowledge, real-life experiences, valuable case studies & dedicated Q&A sessions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180620005048/en/ Leading female AI